Change of Largest Shareholder to Bukwang Pharmaceutical via Third-Party Allotment under Rehabilitation Plan… Existing Shareholders Diluted by 75%, Short-Term Stock Pressure Expected
Change of Largest Shareholder: From Park Kwang-seok (16.09%) to Bukwang Pharmaceutical (75.14%). Bukwang acquires 60 million new shares (KRW 300 billion), securing control.
Purpose of Fundraising: Proceeds (KRW 300 billion) will be used to repay rehabilitation secured claims and rehabilitation claims, aiming to normalize operations.
Impact on Shareholder Value: Existing shareholders' stake drops from 16.09% to 3.95%. New share issuance is 7.6 times the existing outstanding shares (~7.91 million), causing extreme dilution.
Background of New Largest Shareholder: Bukwang Pharmaceutical is a KOSPI-listed drug company (total assets KRW 476.3 billion, 2025 revenue KRW 200.7 billion, net profit KRW 12.4 billion). Its largest shareholder is OCI Holdings (17.11%).
Stock Outlook and Risk: Hopes for business normalization post-rehabilitation vs. heavy dilution pressure. Short-term downside risk due to increased float.
[AI Comprehensive Analysis]This disclosure represents an inevitable capital expansion under the rehabilitation plan, which is a clear negative for existing shareholders due to extreme dilution. However, Bukwang Pharmaceutical's financial strength and operational base may enable medium- to long-term value recovery, so both short-term shock and long-term rebound potential should be considered.